We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GSK will pay $225 million upfront and make a $120 million equity investment in Vir and could pay an additional $500 million in development options. Read More
Eli Lilly has inked a global licensing deal with Rigel Pharmaceuticals for the company’s investigational anti-inflammatory drug, R552, in a pact worth potentially $960 million. Read More
GlaxoSmithKline (GSK) and Vir Biotechnology have teamed up to develop monoclonal antibodies for respiratory viruses, building off an existing agreement struck last year to develop COVID-19 therapies. Read More
The World Health Organization (WHO)’s COVAX initiative is set to begin distributing vaccines to low- and middle-income nations this month, following the organization’s approval of an emergency-use listing of the AstraZeneca (AZ)/Oxford vaccine. Read More
GlaxoSmithKline (GSK) has agreed to sell off its cephalosporin antibiotics product line to Novartis’ generics wing, Sandoz, for $350 million. Read More
The companies have decided to end their research on ziritaxestat after a review of unblinded data concluded that the drug had an unacceptable benefit-risk profile. Read More
Fresenius Kabi Oncology (FKO) has agreed to plead guilty to hiding and destroying records prior to a 2013 FDA inspection and will hand over $50 million in fines and forfeiture, the U.S. Department of Justice revealed. Read More
AstraZeneca said it is “exploring options” with German manufacturer IDT Biologika to boost the supply of its vaccine in Europe during the second quarter of the year. Read More
A Government Accountability Office (GAO) review of COVID-19 vaccine development efforts found that vaccine producers are facing significant manufacturing hurdles as they scale up operations. Read More